Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
vorolanib
- Development stage
- Phase 3
- Lead developer
- EyePoint Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Oral, Intravitreal
01
Overview
Vorolanib is a next-generation, orally administered small-molecule multi–tyrosine kinase inhibitor that targets all isoforms of vascular endothelial growth factor receptor (VEGFR) and platelet-derived growth factor receptor (PDGFR). By inhibiting these receptor tyrosine kinases, vorolanib blocks tumor angiogenesis and cell proliferation, leading to tumor cell death. It has been developed for both oncology indications—such as renal cell carcinoma and various solid tumors—and ophthalmic diseases like wet age-related macular degeneration (wAMD) and diabetic macular edema (DME), where it is formulated as a sustained-release intravitreal implant (EYP 1901). Vorolanib has demonstrated efficacy in combination with other agents such as everolimus or immune checkpoint inhibitors in cancer trials, and its unique mechanism offers potential advantages over traditional anti–VEGF therapies in eye disease[1][3][4][5][6].
- Brand names
- vorolanib
- Other names
- Fumena
02
Targets
ABCG2 (Breast cancer resistance protein)PRKAA1 (AMP-activated protein kinase alpha catalytic subunit isoform alpha-1)CSF1R (Macrophage colony-stimulating factor receptor)FLT3 (Fms related receptor tyrosine kinase 3)JAK1 (Janus kinase 1)PDGFRB (Platelet-derived growth factor receptor beta)RET (Rearranged during transfection receptor tyrosine kinase)VEGFR2 (Vascular endothelial growth factor receptor 2)KIT (c-KIT proto-oncogene receptor tyrosine kinase)
Beyond the preview
Go deeper on vorolanib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on vorolanib.